From April 1, 2023 to June 30, 2023, the company has repurchased 173,900 shares, representing 1.44% for CAD 1.28 million. With this, the company has completed the repurchase of 226,700 shares, representing 1.87% for CAD 1.67 million under the buyback announced on December 13, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9 CAD | +5.88% | +5.88% | -2.39% |
17/05 | BioSyent Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
17/05 | BioSyent Inc Declares Second Quarter 2024 Dividend, Payable June 15, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.39% | 76.63M | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- RX Stock
- News BioSyent Inc.
- Tranche Update on BioSyent Inc. (TSXV: RX)'s Equity Buyback Plan announced on December 13, 2022.